WILPO Drug Patent Profile
✉ Email this page to a colleague
When do Wilpo patents expire, and when can generic versions of Wilpo launch?
Wilpo is a drug marketed by Sandoz and is included in one NDA.
The generic ingredient in WILPO is phentermine hydrochloride. There are seventeen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the phentermine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Wilpo
A generic version of WILPO was approved as phentermine hydrochloride by ELITE LABS INC on May 30th, 1997.
Summary for WILPO
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 44 |
Patent Applications: | 909 |
Formulation / Manufacturing: | see details |
DailyMed Link: | WILPO at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for WILPO
US Patents and Regulatory Information for WILPO
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sandoz | WILPO | phentermine hydrochloride | TABLET;ORAL | 012737-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |